FDA questions the return of GSK's Blenrep in multiple myeloma ahead of adcomm

The FDA is questioning whether GSK has done enough to show that Blenrep should return to the market as a second-line multiple myeloma treatment ahead of a Thursday advisory committee meeting. Agency briefing documents released ...